Is CBAY undervalued or overvalued?

As of 2025-03-16, the Intrinsic Value of Cymabay Therapeutics Inc (CBAY) is (28.74) USD. This CBAY valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 32.48 USD, the upside of Cymabay Therapeutics Inc is -188.50%. This means that CBAY is overvalued by 188.50%.

The range of the Intrinsic Value is (234.75) - (15.56) USD

Note: result may not be accurate due to the invalid valuation result of DCF model.

	Range	Selected	Upside
a
DCF (Growth 5y)	(234.75) - (15.56)	(28.74)	-188.5%
DCF (Growth 10y)	(16.51) - (226.30)	(29.20)	-189.9%
DCF (EBITDA 5y)	(8.37) - (10.02)	(1,234.50)	-123450.0%
DCF (EBITDA 10y)	(10.25) - (12.69)	(1,234.50)	-123450.0%
Fair Value	-4.59 - -4.59	-4.59	-114.13%
P/E	(15.16) - (19.22)	(17.51)	-153.9%
EV/EBITDA	(7.66) - (7.32)	(8.56)	-126.3%
EPV	(5.65) - (7.95)	(6.80)	-120.9%
DDM - Stable	(15.20) - (266.62)	(140.91)	-533.8%
DDM - Multi	(13.32) - (183.06)	(24.91)	-176.7%